Triple
T6003724
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Loxo Oncology |
E133655
|
entity |
| Predicate | developedDrug |
P73
|
FINISHED |
| Object |
LOXO-195
LOXO-195 is a next-generation, highly selective TRK inhibitor developed to treat cancers that have developed resistance to earlier TRK-targeted therapies.
|
E564270
|
NE FINISHED |
Provenance (5 batches)
| Stage | Batch ID | Job type | Status |
|---|---|---|---|
| creating | batch_69c00872444c8190bfaf1739dcec765c |
elicitation | completed |
| NER | batch_69c0560bae148190ad4755defaaf471b |
ner | completed |
| NED1 | batch_69c11365741c819097a43a49dd2428c1 |
ned_source_triple | completed |
| NED2 | batch_69c115acfe748190b91c88df81c2e1c2 |
ned_description | completed |
| NEDg | batch_69c1153b6ce8819090a13d349ccd2d6c |
nedg | completed |
Created at: March 22, 2026, 4:06 p.m.